

References

S-97

1. Guidelines for Surgery and Procedures Performed in the Inpatient Setting. Change Healthcare LLC. 2018
2. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). 2014.
3. Thiruchelvam N. Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. *Indian J Urol.* 2014; 30(2):202–207.
4. Wang MQ, Guo LP, Zhang GD, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: Results of midterm follow-up from Chinese population. *BMC Urol.* 2015; 15(1):33.
5. Crouzet S, Chapelon JY, Rouvière O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients. *Eur Urol.* 2014; 65(5):907-914.
6. Wenger H, Yousef A, Oto A, et al. Laser Ablation as focal therapy for prostate cancer. *Curr Opin Urol.* 2014;24(3):236-40.
7. Roehrborn CG, Gange SN, Shore ND, et al. Durability of the prostatic urethral lift: 2-year results of the L.I.F.T. study. *Urol Pract.* 2015; 2:1-7.
8. Shore N, Freedman S, Gance S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can Urol.* 2014; 21(1):7094-7101.
9. Cantwell AL, Bogache WK, Richardson SF, et al. Multi-center prospective crossover study of the prostatic urethral lift for the treatment of LUTS secondary to BPH. *BJU Int.* 2014;113(4):615-22.
10. McVary KT, Gange SN, Shore ND, et al. Treatment of LUTS secondary to BPH while preserving sexual function: Randomized controlled study of prostatic urethral lift. *J Sex Med.* 2014;11(1):279-87.
11. Shore N. A review of the prostatic urethral lift for lower urinary tract symptoms: Symptom relief, flow improvement, and preservation of sexual function in men with benign prostatic hyperplasia. *Curr Bladder Dysfunct Rep.* 2015.
12. National Institute for Clinical Excellence [NICE] United Kingdom: Interventional procedure guidance guideline for insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2014.

13. Peyton CC, Badlani GH. The management of prostatic obstruction with urethral stents. *Can J Urol*. 2015;75-81.
14. Aoun F, Marcelis Q, Roumeguere T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: Technology update. *Res Rep Uro*. 2015;125-136.
15. Alkhorayef M, Mahmoud MZ, Alzimami KS, et al. High-intensity focused ultrasound (HIFU) in localized prostate cancer treatment. *Pol J Radiol*. 2015;131-141.
16. Robertson C, Sliwinski A, Wallen E, et al. United States experience with primary HIFU therapy for patients with low-risk prostate cancer: Results of the Enlight trial. *J of Ther US*. 2014;12-16.
17. Li Q, Wang MQ, Zhang GD, et al. Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: Preliminary results. *Chin Med J*. 2015;2072-2077.
18. Tholomier C, Valdivieso R, Hueber P, et al. Photoselective laser ablation of the prostate: A review of the current 2015 tissue ablation options. *Can J Urol*. 2015;45-52.
19. Lepor H, Llukani E, Sperling D, et al. Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. *Eur Assoc Urol*. 2015; 924-926.
20. Lee T, Mendhiratta N, Sperling D, et al. Focal laser ablation for localized prostate cancer: Principles, clinical trials, and our initial experience. *Rev Urol*. 2014;55-66.
21. Perera M, Roberts MJ, Doi SAR, et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: A systematic review and meta-analysis. *Eur Assoc Urol*. 2014;714-715.
22. Doyle C. Study: BPH procedure's benefits sustained at 3 years. *Urology Times*. 2015; 1.
23. Zang Y, Deng X, Shan Y, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: A systematic review with meta-analysis of randomized controlled trials. *Lasers Med Sci*. 2016;31(2):235-240.
24. Sun N, Fu Y, An W, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial (RCT). *Int Urol and Nephrol*. 2014;46(7):1277-1282.
25. Hayes, Inc. Hayes Medical Technology Brief. *Rezum System*. Lansdale, PA: Hayes, Inc. Published February 28, 2018. Accessed on August 1, 2019.
26. Hayes, Inc. Hayes Medical Technology Brief. *Urolift System for the Treatment of Benign Prostatic Hyperplasia*. Lansdale, PA: Hayes Inc. Published November 9, 2017. Accessed on August 1, 2019.
27. Hayes Health Technology Brief. *High-Intensity Focused Ultrasound for Salvage Therapy of Recurrent Prostate Cancer*. Lansdale, PA: Hayes, Inc. Published March 2017. Reviewed March 2018. Accessed June 14, 2018.
28. Hayes, Inc. Hayes Medical Technology Directory Report. *Comparative Effectiveness Review of Cryoablation for Primary Treatment of Localized Prostate Cancer*. Lansdale, PA: Hayes, Inc. July 23, 2017. Accessed August 2, 2019.

29. Gao L, Yang L, Qian S, et al. Cryosurgery would be an effective option for clinically localized prostate cancer: a meta-analysis and systematic review. *Sci Rep*. 2016; 6:27490.
30. American Urological Association. Published 2018. Retrieved from [http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-\(aua/astro/suo-guideline-2017\)](http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)). Accessed on August 1, 2019.
31. Prostate Cancer: Treatment Options. American Society of Clinical Oncology (ASCO). Retrieved from www.cancer.net. Accessed June 14, 2018.
32. American Urological Association (AUA). Guidelines on Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. 2018. Amended 2019. [https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(bph\)-guideline](https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline). Accessed August 1, 2019
37. National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management. 2010. Updated 2015. <https://www.nice.org.uk/guidance/cg97/chapter/1-Recommendations>. Accessed August 1, 2019.
38. Jacome-Pita F, Sanchez-Salas R, Barret E, et al. Focal therapy in prostate cancer: the current situation. *Ecanermedicalscience*. 2014; 8:435.
39. Tay KJ, Mendez M, Moul JW, Polascik T. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? *Curr Opin Urol*. 2015;25(3):185-190.
40. Passoni NM, Polascik TJ. How to select the right patients for focal therapy of prostate cancer? *Curr Opin Urol*. 2014;24(3):203-208.
41. Van Den Bos W, Muller BG, Ahmed H, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. *Eur Urol*. 2014;65(6):1078-1083.
42. National Institute for Health and Care Excellence (NICE). Focal Therapy Using Cryoablation for Localised Prostate Cancer [IPG423]. 2012; <https://www.nice.org.uk/guidance/ipg423/chapter/1-guidance>. Accessed August 7, 2018.
43. National Institute for Health and Care Excellence (NICE). Focal Therapy Using High-Intensity Focused Ultrasound for Localized Prostate Cancer [IPG424]. 2012; <https://www.nice.org.uk/guidance/ipg118>. Accessed August 8, 2018.
44. Valerio M, Ahmed HU, Emberton M, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. *Eur Urol*. 2014; 66(4):732-751.
45. Wolff RF, Ryder S, Bossi A, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. *Eur J Cancer*. 2015; 51(16):2345-2367.
46. Natarajan S, Raman S, Priester AM, et al. Focal laser ablation of prostate cancer: phase I clinical trial. *J Urol*. 2016; 196(1):68-75.
47. Lian H, Zhuang J, Yang R, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. *Int Urol Nephrol*. 2016; 48(1):85-90.
48. Mendez MH, Passoni NM, Pow-Sang J, et al. Comparison of outcomes between preoperatively potent men treated with focal versus whole gland cryotherapy in a matched population. *J Endourol*. 2015; 29(10):1193-1198.
49. Gill IS, Azzouzi AR, Emberton M, et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. *J Urol*. 2018.
50. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: prostate

cancer.https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed August 2, 2019.

51. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management [NG131] 2019; <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#localised-and-locally-advanced-prostate-cancer>. Accessed August 2, 2019.
52. National Cancer Institute. Prostate Cancer Treatment (PDQ®)-Patient Version: Treatment Option Overview. 2018; https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq#_142 Accessed August 10, 2018.
53. U.S. Preventive Services Task Force. Final Recommendation Statement: Prostate Cancer: Screening. 2018; <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1>. Accessed August 10, 2018.
54. UpToDate. Medical treatment of benign prostatic hyperplasia. 2019. Available at: https://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia?search=benign%20prostatic%20hyperplasia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed May 28, 2019.
55. Westwood JJ, Geraghty RR, Jones, PP, Rai, BB, Somani, BB. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol*, 2018; 23:10(11).
56. McVary KK, Roehrborn CC. Three-Year Outcomes of the Prospective, Randomized Controlled Rezum System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. *Urology*. 2017; 111:1-9.
57. McVary KK, Gange SS, Gittelman MM, et al. Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *J Urol*. 2015; 195(5).
58. McVary KK, Rogers TT, Roehrborn CC. Rezum Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. *Urology*, 2019; 126:171-179.
59. Siegel RL, Miller KD, Jemal A. *Cancer Statistics*.2017;1:7-30.
60. Elkjaer MC, Borre M. Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience. *Scand J Urol*. 2014; 48(1):27-33.
61. Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. 2015; 19(49):1-490.
62. Xiong T, Turner RM, Wei Y, et al. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. *BMJ Open*. 2014; 4(5):e004285.
63. Tay KJ, Polascik TJ, Elshafei A, et al. Primary cryotherapy for high-grade clinically localized prostate cancer: oncologic and functional outcomes from the COLD Registry. *J Endourol*. 2016; 30(1):43-48.
64. Siddiqui KM, Billia M, Al-Zahrani A, et al. Long-term oncologic outcomes of salvage cryoablation for radio-recurrent prostate cancer. *J Urol*. 2016;196(4):1105-1111.
65. Friedlander DF, Gu X, Prasad SM, et al. Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. *Urology*. 2014; 83(3):653-657.
66. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2017; 71(4):618-629.
67. European Association of Urology (EAU). EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. 2017; https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_2017_web.pdf. Accessed June 21, 2018.
68. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Cryosurgery of Prostate (230.9). 2001; <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=123&bc=AgAAQAAAAAAA&ncdver=1>. Accessed August 1, 2019.

69. Hayes Inc. Hayes Medical Technology Directory Report. *Comparative Effectiveness Review of Cryoablation for Salvage Treatment of Recurrent Prostate Cancer Following Radiotherapy*. Lansdale, PA: Hayes, Inc.; July, 2018. August 1, 2019.
70. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Usui Y, Nagata Y. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. *BJU international*. 2011; 107(3):378-82.
71. Nair SM, Pimentel MA, Gilling PJ. A review of laser treatment for symptomatic BPH (benign prostatic hyperplasia). *Curr Urol Rep*. 2016; 17(6): p.45.
72. Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. *J Urol*. 2018.
73. Sundaram D, Sankaran PK, Raghunath G, et al. Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms. *J Clin Diagn Res*. 2017; 11(5):AC01-AC04.
74. Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*. 2015; 68(4):643-652.
75. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*. 2015; 22(3):7772-7782.
76. Jones P, Rajkumar GN, Rai BP, et al. Medium-term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. *Urology*. 2016; 97:20-24.
77. Bozkurt A, Karabakan M, Keskin E, et al. Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Int*. 2016; 96(2):202-206.
78. Ray A, Morgan H, Wilkes A, Carter K, Carolan-Rees G. The Urolift System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a NICE Medical Technology Guidance. *Appl Health Econ Health*. 2016; 14(5):515-526.
79. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int*. 2017; 119(5):767-775.
80. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*. 2017; 24(3):8802-8813.
81. Rukstalis D, Rashid P, Bogache WK, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. *BJU Int*. 2016; 118(Suppl 3):14-22.
82. Roehrborn CG. Prostatic urethral lift: a unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Clin North Am*. 2016; 43(3):357-369.
83. National Institute for Health and Care Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia [IPG475]. 2014; <https://www.nice.org.uk/guidance/ipg475/chapter/1-recommendations>. Accessed July 20, 2018.
84. National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia [MTG26]. 2015; <https://www.nice.org.uk/guidance/mtg26>. Accessed July 20, 2018.

